SanBio (4592) · InitiativeAdvanced
U.S. Patent Granted for SB623’s Use in Retinal Degenerative Diseases
First written in FY2017-Q2. 1 of 2 entries say "Advanced", first in FY2017. Latest entry: FY2017.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
SB623 patent acquisition for use in retinal degenerative diseasesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2017AdvancedAnnual report
「During the current consolidated fiscal year, the Company completed the acquisition of a U.S. patent for SB623's use in retinal degenerative diseases and an Australian patent for its use in traumatic brain injury, among others.」
Completion of the U.S. patent acquisition for use in retinal degenerative diseases was reconfirmed, and completion of the Australian patent acquisition for use in traumatic brain injury was also indicated. - FY2017-Q2First statedAnnual report
「Regarding patents, in May 2016, the Company obtained from the United States Patent and Trademark Office (USPTO) a patent for SB623's use in retinal degenerative diseases (U.S. Patent No. 9,326,999 B2).」
In May 2016, the Company obtained a patent from the United States Patent and Trademark Office for SB623's use in retinal degenerative diseases.